NASD
| Health Care |
Biotechnology
Regulus Therapeutics Inc. (RGLS)
LAST (3 Apr)
After-Hours (19:38:41 ET)
MARKET CAP
VOLUME
| Open | 1.81 |
| Previous Close | 1.96 |
| Day Range | 1.73 - 1.95 |
| 52-Week Range | 0.83 - 2.90 |
| All-Time High | 3,072.00 |
| Avg. Volume (50-day) | 1,306,860.5 |
| EPS (TTM) | -0.88 |
| Next Earnings Date | 2025-05-08 (AMC) |
| Last Earnings Date | 2025-03-13 |
| Forward Annual Dividend (Yield) | - |
| Trailing Annual Dividend (Yield) | - |
| Options | Yes |
| P/E Ratio | -2.24 |
| PEG Ratio | - |
| Price to Book | 1.68 |
| Price to Cash Flow | - |
| Price to Free Cash Flow | - |
| Total Sales (TTM) | - |
| Revenue per Share (TTM) | - |
| Shares Outstanding | 66.243 M |
| Share Float (%) | 53.18 M |
| % Held by Institutions | 63.67 |
| Dividends Per Share (TTM) | - |
| Ex-Dividend Date | - |
| +/- EMA(20) | 1.54 (+16.88%) |
| +/- SMA(50) | 1.33 (+35.34%) |
| +/- SMA(200) | 1.54 (+16.88%) |
| 5-Day Perf. | +20% |
| 1-Month Perf. | +42.86% |
| 3-Month Perf. | +11.8% |
| 6-Month Perf. | +10.43% |
| YTD Perf. | +13.92% |
| 1-Year Perf. | -31.03% |
| RSI(14) | 63.8 |
| ATR(14) | 0.2 |
| ADX(14) | 36.18 |
| Beta (5Y) | 0.83 |
FOR STOCKCHARTS MEMBERS ONLY
Unlock earnings and revenue history when you join StockCharts
As a StockCharts Member, you can review earnings results and analyze revenue and earnings growth over time. Bring a balance of technicals and fundamentals to your approach when you join today!
RGLS
Regulus Therapeutics Inc.
Sector: Health Care
Industry: Biotechnology
Employees: 34
Description
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.
RGLS has triggered the following predefined scans:
| Elder Bar Turned Blue |
| Bearish Harami |
| P&F Low Pole |
FOR STOCKCHARTS MEMBERS ONLY
Unlock custom technical alerts when you join StockCharts
As a StockCharts Member, you can create your own unique alerts with the technical criteria that matters most to you. Stay ahead of important moves and never miss a thing in the markets.
FOR STOCKCHARTS MEMBERS ONLY
Unlock ChartLists to save and organize your charts when you join StockCharts
As a StockCharts Member, you can save the charts you're watching to your own account with ChartLists. Accessible from any device, you can organize, review and analyze your charts on-the-go, anytime, anywhere.
